PinnyPeptide

GDF-8 95 (Myostatin Inhibitor) vs IGF-1 LR3

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

GDF-8 95 (Myostatin Inhibitor)

Muscle Growth

Short-peptide myostatin inhibitor targeting the GDF-8 / activin RIIB pathway.

Peptide B

IGF-1 LR3

Muscle Growth

Long-acting IGF-1 analog with reduced binding-protein affinity for sustained signaling.

Typical vial

1 mg

Typical dose

50-200 mcg

Half-life

Variable / poorly characterized for short-peptide formulations

FDA status

Not FDA approved.

Typical vial

1 mg

Typical dose

20-50 mcg

Half-life

~20-30 hours

FDA status

Not FDA approved. Native recombinant rhIGF-1 (mecasermin/Inc…

GDF-8 95 (Myostatin Inhibitor) effects

  • Theoretical inhibition of myostatin signaling
  • Potential muscle hypertrophy via removal of myostatin brake
  • Limited direct evidence for short-peptide formulations in humans
  • Mechanistic rationale supported by pathway biology

IGF-1 LR3 effects

  • Sustained IGF-1 receptor activation (20-30 hour half-life)
  • Muscle cell hyperplasia (increased cell number, not just size)
  • Anabolic signaling via PI3K-Akt-mTOR pathway
  • Improved nutrient partitioning toward muscle
  • Enhanced recovery from training-induced damage

GDF-8 95 (Myostatin Inhibitor) side effects

  • Largely uncharacterized in humans
  • Theoretical: capillary leak if cross-reactivity with other TGF-β ligands occurs
  • Injection-site reactions
  • Possible immunogenicity (anti-drug antibody formation)

IGF-1 LR3 side effects

  • Hypoglycemia (real risk — IGF-1 has insulin-like activity)
  • Joint pain and stiffness
  • Carpal tunnel-like symptoms
  • Lethargy / lightheadedness from glucose drops
  • Possible tumor-promoting effects (theoretical, dose-dependent)
  • Localized lipohypertrophy or muscle asymmetry with site injection

GDF-8 95 (Myostatin Inhibitor) dosing ranges

Research / muscle hypertrophy

50-200 mcg · Daily or twice-weekly (SubQ) · Per research protocol

IGF-1 LR3 dosing ranges

Research / muscle hypertrophy

20-50 mcg · Once daily (SubQ or IM), pre- or post-workout · 30-50 days per cycle

Site-specific injection (research)

20-40 mcg per site · Into trained muscle, post-workout · 30-50 days per cycle

GDF-8 95 (Myostatin Inhibitor) vs IGF-1 LR3 — common questions

What is the difference between GDF-8 95 (Myostatin Inhibitor) and IGF-1 LR3?

GDF-8 95 (Myostatin Inhibitor): Short-peptide myostatin inhibitor targeting the GDF-8 / activin RIIB pathway. Typical dose 50-200 mcg. IGF-1 LR3: Long-acting IGF-1 analog with reduced binding-protein affinity for sustained signaling. Typical dose 20-50 mcg. Both fall under the Muscle Growth category.

Can you stack GDF-8 95 (Myostatin Inhibitor) and IGF-1 LR3?

Stacking GDF-8 95 (Myostatin Inhibitor) with IGF-1 LR3 is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, GDF-8 95 (Myostatin Inhibitor) or IGF-1 LR3?

GDF-8 95 (Myostatin Inhibitor) is typically dosed: Daily or twice-weekly (SubQ) for Research / muscle hypertrophy. IGF-1 LR3 is typically dosed: Once daily (SubQ or IM), pre- or post-workout for Research / muscle hypertrophy; Into trained muscle, post-workout for Site-specific injection (research).

Are GDF-8 95 (Myostatin Inhibitor) and IGF-1 LR3 FDA approved?

GDF-8 95 (Myostatin Inhibitor): Not FDA approved. IGF-1 LR3: Not FDA approved. Native recombinant rhIGF-1 (mecasermin/Increlex) is FDA approved for severe primary IGF-1 deficiency in children, but IGF-1 LR3 itself is not.

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free